Cynata Therapeutics trial misses main targets at 24 months
- Cynata Therapeutics reported top-line results from its Phase 3 trial of CYP-004, which showed no statistically significant differences between the active and control groups.
- The company's share price remained unchanged at $0.26 following the announcement due to a voluntary trading suspension.
- The company stated that it is now actively reviewing options for the further development of its proprietary Cymerus technology platform.
Cynata Therapeutics (ASX:CYP) announced its Phase 3 trial of CYP-004 showed no statistically significant differences, with 51.7% of active participants reaching the patient-acceptable symptom state compared to 48.1% in the control group.
The results contrast with previous trial achievements after the company completed final participant visits in late 2025.
“The results of this trial are disappointing,” said Cynata Therapeutics CEO and Managing Director Dr Kilian Kelly.
Secondary findings showed an average pain reduction score of 26.8/100 in the active group and 25.3/100 in the control group after 24 months.
Following the announcement, the Cynata Therapeutics share price was unchanged at $0.26.
The company stated that it is actively reviewing options for further development of the Cymerus technology following these outcomes and recent Phase 2 data.
Previously, the company secured commitments for a $1.5 million institutional placement in May to support its ongoing commercial partnership discussions.
